GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » Equity-to-Asset

Relmada Therapeutics (Relmada Therapeutics) Equity-to-Asset : 0.88 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Relmada Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $85.36 Mil. Relmada Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $97.55 Mil.

The historical rank and industry rank for Relmada Therapeutics's Equity-to-Asset or its related term are showing as below:

RLMD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.81   Med: 0.75   Max: 0.93
Current: 0.88

During the past 11 years, the highest Equity to Asset Ratio of Relmada Therapeutics was 0.93. The lowest was -1.81. And the median was 0.75.

RLMD's Equity-to-Asset is ranked better than
82.32% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs RLMD: 0.88

Relmada Therapeutics Equity-to-Asset Historical Data

The historical data trend for Relmada Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Equity-to-Asset Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.89 0.93 0.92 0.88

Relmada Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.93 0.91 0.92 0.88

Competitive Comparison of Relmada Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Relmada Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Equity-to-Asset falls into.



Relmada Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Relmada Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=85.357/97.552
=

Relmada Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=85.357/97.552
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relmada Therapeutics  (NAS:RLMD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Relmada Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics (Relmada Therapeutics) Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Executives
Cedric O'gorman officer: Chief Medical Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli director C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa director, officer: Chief Executive Officer 138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly director 300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel officer: EVP, Head of R&D 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence officer: Chief Financial Officer 3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo officer: Chief Medical Officer 71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar director P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas officer: President and CSO 7707 GATEWAY BLVD, NEWARK CA 94560

Relmada Therapeutics (Relmada Therapeutics) Headlines

From GuruFocus